Chai Discovery has raised $400 million in Series C financing, valuing the AI drug design startup at $3.8 billion. The company says its platform—used by large pharma partners such as Eli Lilly and Pfizer—generates novel molecular designs and has progressed from improved target-binding performance with Chai-2 to material advances claimed with Chai-3, including tighter antibody binding.